Michael Krainer
- Oncology top 2%
- Cancer Treatment and Pharmacology 11
- HER2/EGFR in Cancer Research 9
- Cancer Cells and Metastasis 8
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 7
- Hematology top 2%
- Multiple Myeloma Research and Treatments 7
- Immunology top 5%
- Reproductive Medicine top 5%
-
- Prostate Cancer Treatment and Research 22
-
- Cell death mechanisms and regulation 10
-
- Radiopharmaceutical Chemistry and Applications 7
- Co-authors
- Dietmar PilsRobert ZeillingerPeter HorakChristoph ZielinskiDaniel A. HaberReinhard HorvatE. FritzKurt J. Isselbacher
- Cited by
- OncologyCancer ResearchHematology
- Journals
- European Journal of Cancer (7 papers)Journal of Clinical Oncology (6 papers)Cancer (5 papers)
- Partner nations
- AustriaUnited StatesFrance
In The Last Decade
Michael Krainer
105 papers receiving 3.4k citations
Peers
Comparison fields: 5 of 110
- Oncology 1.5k
- Cancer Research 692
- Hematology 428
- Immunology 767
- Reproductive Medicine 189
Countries citing papers authored by Michael Krainer
This map shows the geographic impact of Michael Krainer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Krainer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Krainer more than expected).
Fields of papers citing papers by Michael Krainer
This network shows the impact of papers produced by Michael Krainer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Krainer. The network helps show where Michael Krainer may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michael Krainer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 7 | |
| 2 | 2021 | 24 | |
| 3 | 2020 | 15 | |
| 4 | 2016 | 2 | |
| 5 | 2015 | 10 | |
| 6 | 2014 | 72 | |
| 7 | 2014 | 47 | |
| 8 | 2011 | 37 | |
| 9 | 2010 | 16 | |
| 10 | 2007 | 51 | |
| 11 | N33 (TUSC3) promoter hypermethylation in serum of prostate cancer patients | 2006 | 2 |
| 12 | Hypermethylation of N33 (TUSC3) as independent molecular predictor for ovarian cancer | 2006 | 2 |
| 13 | 2005 | 3 | |
| 14 | Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. | 2004 | 25 |
| 15 | 2004 | 50 | |
| 16 | 2001 | 21 | |
| 17 | 1998 | 12 | |
| 18 | 1997 | 72 | |
| 19 | 1997 | 66 | |
| 20 | 1997 | 30 |
About Michael Krainer
Michael Krainer is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Hematology, having authored 106 papers that have together received 3.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (22 papers), Cancer Treatment and Pharmacology (11 papers), Cell death mechanisms and regulation (10 papers), HER2/EGFR in Cancer Research (9 papers), Cancer Cells and Metastasis (8 papers), Cancer Genomics and Diagnostics (7 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Multiple Myeloma Research and Treatments (7 papers). The work is most often cited by research in Oncology (1.5k citations), Cancer Research (692 citations), Hematology (428 citations), Immunology (767 citations) and Reproductive Medicine (189 citations). Michael Krainer has collaborated with scholars based in Austria, United States and France. Frequent co-authors include Dietmar Pils, Robert Zeillinger, Peter Horak, Christoph Zielinski, Daniel A. Haber, Reinhard Horvat, E. Fritz, Kurt J. Isselbacher, Michael G. FitzGerald and Sandra Tomek. Their work appears in journals such as European Journal of Cancer, Journal of Clinical Oncology, Cancer, Cancers and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.